Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
The efficiency of first-generation adenoviral vectors as gene delivery tools is often limited by the short duration of transgene expression, which can be related to immune responses and to toxic effects of viral proteins. In addition, readministration is usually ineffective unless the animals are immunocompromised or a different adenovirus serotype is used. Recently, adenoviral vectors devoid of all viral coding sequences (helper-dependent or gutless vectors) have been developed to avoid expression of viral proteins. In mice, liver-directed gene transfer with AdSTK109, a helper-dependent adenoviral (Ad) vector containing the human α 1 -antitrypsin (hAAT) gene, resulted in sustained expression for longer than 10 months with negligible toxicity to the liver. In the present report, we have examined the duration of expression of AdSTK109 in the liver of baboons and compared it to first-generation vectors expressing hAAT. Transgene expression was limited to approximately 3–5 months with the first-generation vectors. In contrast, administration of AdSTK109 resulted in transgene expression for longer than a year in two of three baboons. We have also investigated the feasibility of circumventing the humoral response to the virus by sequential administration of vectors of different serotypes. We found that the ineffectiveness of readministration due to the humoral response to an Ad5 first-generation vector was overcome by use of an Ad2-based vector expressing hAAT. These data suggest that long-term expression of transgenes should be possible by combining the reduced immunogenicity and toxicity of helper-dependent vectors with sequential delivery of vectors of different serotypes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy.
Yang, Y., Nunes, F. A., Berencsi, K., Furth, E. E., Gönczöl, E., & Wilson, J. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.10.4407 · Cited by 1,575
Construction of adenovirus vectors through Cre-lox recombination
Hardy, S., Kitamura, M., Harris-Stansil, T., Dai, Y., & Phipps, M. L. (1997) · Journal of Virology · doi:10.1128/jvi.71.3.1842-1849.1997 · Cited by 789
Adenovirus-Mediated Transfer of a Recombinant α1-Antitrypsin Gene to the Lung Epithelium in Vivo
Rosenfeld, M. A., Siegfried, W., Yoshimura, K., Yoneyama, K., Fukayama, M., Stier, L. E., Pääkkö, P. K., Gilardi, P., Stratford-Perricaudet, L. D., Perricaudet, M., et al. (1991) · Science · doi:10.1126/science.2017680 · Cited by 737
Parks, R. J., Chen, L., Anton, M., Sankar, U., Rudnicki, M. A., & Graham, F. L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13565 · Cited by 725
Self-citationSchiedner, G., Morral, N., Parks, R. J., Wu, Y., Koopmans, S. C., Langston, C., Graham, F. L., Beaudet, A. L., & Kochanek, S. (1998) · Nature Genetics · doi:10.1038/ng0298-180 · Cited by 648
Self-citationTripathy, S. K., Black, H. B., Goldwasser, E., & Leiden, J. M. (1996) · Nature Medicine · doi:10.1038/nm0596-545 · Cited by 628
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Kochanek, S., Clemens, P. R., Mitani, K., Chen, H. H., Chan, S., & Caskey, C. T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.12.5731 · Cited by 562
Self-citationInnate Immune Mechanisms Dominate Elimination of Adenoviral Vectors Following In Vivo Administration
Worgall, S., Wolff, G., Falck-Pedersen, E., & Crystal, R. G. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.1-37 · Cited by 491
Adenovirus–mediated in vivo gene transfer and expression in normal rat liver
Jaffe, H. A., Danel, C., Longenecker, G., Metzger, M., Setoguchi, Y., Rosenfeld, M. A., Gant, T. W., Thorgeirsson, S. S., Stratford-Perricaudet, L. D., Perricaudet, M., et al. (1992) · Nature Genetics · doi:10.1038/ng0892-372 · Cited by 449
Cited by
Progress and problems with the use of viral vectors for gene therapy
Thomas, C. E., Ehrhardt, A., & Kay, M. A. (2003) · Nature Reviews Genetics · doi:10.1038/nrg1066 · Cited by 2,501
“Humoral immune responses against adenovirus and AAV vectors have been addressed by switching capsid SEROTYPES , but antibody responses towards secreted therapeutic proteins remain a theoretical problem for the long-term therapy of certain disorder”
BackgroundViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
Viral and nonviral delivery systems for gene delivery
Nayerossadat, N., Maedeh, T., & Ali, P. (2012) · Advanced Biomedical Research · doi:10.4103/2277-9175.98152 · Cited by 858
Update on adenovirus and its vectors
Russell, W. C. (2000) · Journal of General Virology · doi:10.1099/0022-1317-81-11-2573 · Cited by 596
Gene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
Vogels, R., Zuijdgeest, D., van Rijnsoever, R., Hartkoorn, E., Damen, I., de Béthune, M.-P., Kostense, S., Penders, G., Helmus, N., Koudstaal, W., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.15.8263-8271.2003 · Cited by 467
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Adenovirus serotype 5 hexon is critical for virus infection of hepatocytes in vivo
Kalyuzhniy, O., Di Paolo, N. C., Silvestry, M., Hofherr, S. E., Barry, M. A., Stewart, P. L., & Shayakhmetov, D. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711757105 · Cited by 349
Björklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., & Mandel, R. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02915-2 · Cited by 346
Schnell, M. A., Zhang, Y., Tazelaar, J., Gao, G.-P., Yu, Q. C., Qian, R., Chen, S.-J., Varnavski, A. N., LeClair, C., Raper, S. E., et al. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0330 · Cited by 342
Gutless adenovirus: last-generation adenovirus for gene therapy
Alba, R., Bosch, A., & Chillon, M. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302612 · Cited by 303
Regulatable gene expression systems for gene therapy applications: progress and future challenges
Goverdhana, S., Puntel, M., Xiong, W., Zirger, J. M., Barcia, C., Curtin, J. F., Soffer, E. B., Mondkar, S., King, G. D., Hu, J., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.03.022 · Cited by 283
“HC-Ad vectors have the added advantage of an increased cloning capacity compared to other viral vectors, and due to their reduced immune responses and toxicity, they elicit stable transgene expression in vivo both in peripheral organs and in the central nervous system [4,8,18-23].”
BackgroundImmunity to adenovirus and adeno-associated viral vectors: implications for gene therapy
Jooss, K., & Chirmule, N. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302037 · Cited by 277
Viral vectors for gene delivery to the central nervous system
Lentz, T. B., Gray, S. J., & Samulski, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.09.014 · Cited by 271
Functional, Persistent, and Extended Liver to Pancreas Transdifferentiation
Ber, I., Shternhall, K., Perl, S., Ohanuna, Z., Goldberg, I., Barshack, I., Benvenisti-Zarum, L., Meivar-Levy, I., & Ferber, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303127200 · Cited by 267
Trask, T. W., Trask, R. P., Aguilar-Cordova, E., Shine, H. D., Wyde, P. R., Goodman, J. C., Hamilton, W. J., Rojas-Martinez, A., Chen, S.-H., Woo, S. L. C., et al. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0030 · Cited by 262
Brunetti-Pierri, N., Palmer, D. J., Beaudet, A. L., Carey, K. D., Finegold, M., & Ng, P. (2004) · Human Gene Therapy · doi:10.1089/10430340460732445 · Cited by 256
Self-citationHelper-Dependent Adenoviral Vectors for Gene Therapy
Palmer, D. J., & NG, P. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1 · Cited by 194
Adenoviral Vector Immunity: Its Implications and Circumvention Strategies
S. Ahi, Y., S. Bangari, D., & K. Mittal, S. (2011) · Current Gene Therapy · doi:10.2174/156652311796150372 · Cited by 185
Pastore, N., Blomenkamp, K., Annunziata, F., Piccolo, P., Mithbaokar, P., Maria Sepe, R., Vetrini, F., Palmer, D., Ng, P., Polishchuk, E., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202046 · Cited by 142
Implications of the Innate Immune Response to Adenovirus and Adenoviral Vectors
Gregory, S. M., Nazir, S. A., & Metcalf, J. P. (2011) · Future Virology · doi:10.2217/fvl.11.6 · Cited by 89
“Also, in animal models, the toxicity was decreased, while the duration of transgene expression relative to the earlier-generation AdV vectors was enhanced [197–199].”
BackgroundInnate immunity to adenovirus: lessons from mice
Atasheva, S., Yao, J., & Shayakhmetov, D. M. (2019) · FEBS Letters · doi:10.1002/1873-3468.13696 · Cited by 87
Immunological aspects of recombinant adeno-associated virus delivery to the mammalian brain
Mastakov, M. Y., Baer, K., Symes, C. W., Leichtlein, C. B., Kotin, R. M., & During, M. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.16.8446-8454.2002 · Cited by 87
Gene therapy for age-related macular degeneration
Moore, N. A., Bracha, P., Hussain, R. M., Morral, N., & Ciulla, T. A. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1356817 · Cited by 63
“helper-dependent adenoviral vectors are by far the safest [15,16].”
BackgroundSelf-citationBarriers for retinal gene therapy: separating fact from fiction.
Kumar-Singh, R. (2008) · Vision Research · doi:10.1016/j.visres.2008.05.005 · Cited by 43
Ramo, K., Cashman, S. M., & Kumar-Singh, R. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2025 · Cited by 38
Genetic Modification of the Lung Directed Toward Treatment of Human Disease
Sondhi, D., Stiles, K. M., De, B. P., & Crystal, R. G. (2017) · Human Gene Therapy · doi:10.1089/hum.2016.152 · Cited by 36
Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models
Brunetti-Pierri, N., & Ng, P. (2017) · Virus Genes · doi:10.1007/s11262-017-1471-x · Cited by 32
Li, C., Ding, L., Sun, C.-W., Wu, L.-C., Zhou, D., Pawlik, K. M., Khodadadi-Jamayran, A., Westin, E., Goldman, F. D., & Townes, T. M. (2016) · Scientific Reports · doi:10.1038/srep30422 · Cited by 30
Lena, A. M., Giannetti, P., Sporeno, E., Ciliberto, G., & Savino, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.758 · Cited by 27
Metadata
- Authors
- Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., Wadsworth, S., Graham, F. L., Kochanek, S., Carey, K. D., & Beaudet, A. L.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1999-10-26
- Volume
- 96
- Issue
- 22
- Pages
- 12816-12821
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2160690575
- Cited by
- 409
- References
- 51
- FWCI
- 17.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.